Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.75 +0.5%	$20.17	$16.10 ▼ $41.94	$3.50B	0.78	3.15 million shs	3.88 million shs
MIRM Mirum Pharmaceuticals	$67.93 +4.8%	$52.89	$36.86 ▼ $69.00	$3.41B	0.94	633,666 shs	1.03 million shs
ORIC Oric Pharmaceuticals	$9.66 -2.7%	$10.30	$3.90 ▼ $14.67	$938.21M	1.69	1.30 million shs	650,938 shs
SRRK Scholar Rock	$31.41 -2.7%	$35.73	$6.76 ▼ $46.98	$3.02B	0.48	1.58 million shs	1.78 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+13.87%	+38.47%	+59.03%	-22.96%
MIRM Mirum Pharmaceuticals	0.00%	+13.27%	+28.83%	+50.92%	+63.73%
ORIC Oric Pharmaceuticals	0.00%	+4.55%	-13.29%	+104.23%	-2.13%
SRRK Scholar Rock	0.00%	-1.69%	-26.71%	+2.82%	+241.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.0937 of 5 stars	3.3	1.0	4.4	3.2	2.5	0.6
MIRM Mirum Pharmaceuticals	3.4446 of 5 stars	2.6	0.0	4.2	3.9	1.7	0.6
ORIC Oric Pharmaceuticals	4.7218 of 5 stars	4.5	3.0	4.4	2.2	3.3	0.6
SRRK Scholar Rock	4.4872 of 5 stars	4.6	0.0	4.4	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	22.95% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$74.13	9.12% Upside
ORIC Oric Pharmaceuticals	2.90	Moderate Buy	$17.63	82.45% Upside
SRRK Scholar Rock	3.22	Buy	$45.14	43.72% Upside

Current Analyst Ratings Breakdown

Latest ORIC, APLS, SRRK, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
8/14/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
8/13/2025	ORIC Oric Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/12/2025	ORIC Oric Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$89.00
8/8/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $89.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
8/7/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$79.00 ➝ $81.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$77.00 ➝ $82.00
8/7/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $80.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.49	N/A	N/A	$1.24 per share	22.38
MIRM Mirum Pharmaceuticals	$429.16M	7.95	N/A	N/A	$5.08 per share	13.37
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.34 per share	N/A
SRRK Scholar Rock	$33.19M	90.97	N/A	N/A	$2.43 per share	12.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.21	N/A	N/A	N/A	-13.65%	-24.76%	-8.50%	N/A
ORIC Oric Pharmaceuticals	-$127.85M	-$1.89	N/A	N/A	N/A	N/A	-51.75%	-47.09%	N/A
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	N/A

Latest ORIC, APLS, SRRK, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	-$0.47	-$0.01	-$0.47	N/A	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	-$0.12	+$0.19	-$0.12	$107.91 million	$127.79 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
MIRM Mirum Pharmaceuticals	1.21	3.13	2.97
ORIC Oric Pharmaceuticals	N/A	16.13	12.00
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
MIRM Mirum Pharmaceuticals	N/A
ORIC Oric Pharmaceuticals	95.05%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
MIRM Mirum Pharmaceuticals	14.36%
ORIC Oric Pharmaceuticals	6.82%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
MIRM Mirum Pharmaceuticals	140	50.24 million	43.02 million	Optionable
ORIC Oric Pharmaceuticals	80	97.12 million	90.50 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

ORIC, APLS, SRRK, and MIRM Headlines

Recent News About These Companies

Lord Abbett & CO. LLC Boosts Holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 17 at 5:49 AM | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15 at 4:15 PM | businesswire.com

Scholar Rock publishes SAPPHIRE trial data in The Lancet

August 15 at 2:42 AM | msn.com

Scholar Rock Holding: Upcoming Milestone Approaches

August 13, 2025 | seekingalpha.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by Informed Momentum Co LLC

August 13, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $45.14 Average PT from Brokerages

August 13, 2025 | americanbankingnews.com

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12, 2025 | msn.com

Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock

August 12, 2025 | americanbankingnews.com

Wedbush Issues Negative Forecast for Scholar Rock Earnings

August 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11, 2025 | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Scholar Rock (NASDAQ:SRRK) Stock Price Down 10.2% Following Weak Earnings

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $45.00 at BMO Capital Markets

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Trading Down 10.2% on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down After Earnings Miss

August 7, 2025 | marketbeat.com

Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus

August 7, 2025 | msn.com

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORIC, APLS, SRRK, and MIRM Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.75 +0.13 (+0.47%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$27.88 +0.13 (+0.47%)

As of 08/15/2025 07:53 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$67.93 +3.10 (+4.78%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$67.89 -0.04 (-0.06%)

As of 08/15/2025 07:44 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oric Pharmaceuticals NASDAQ:ORIC

$9.66 -0.27 (-2.72%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$9.78 +0.13 (+1.29%)

As of 08/15/2025 07:13 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Scholar Rock NASDAQ:SRRK

$31.41 -0.88 (-2.73%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$31.74 +0.33 (+1.05%)

As of 08/15/2025 07:33 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time